Biotech By Adam Feuerstein Arcus’ anti-TIGIT immunotherapy shows ‘encouraging’ tumor response, but likely leaves investors wanting more
Biotech By Matthew Herper Peter Bach, industry critic, joins company aiming to make blood tests to detect cancer
Biotech By Matthew Herper, Damian Garde, and Adam Feuerstein Newly disclosed FDA documents reveal agency’s unprecedented path to approving Aduhelm
Exclusive By Olivia Goldhill Athira Pharma CEO placed on leave amid allegations of altered images in her research papers
Biotech By Adam Feuerstein Sage antidepressant achieves goals of large study, but questions about benefit linger
Biotech By Adam Feuerstein GSK pays up big for rights to TIGIT-targeted cancer immunotherapy from Iteos
Biotech By Helen Branswell Novavax Covid-19 vaccine highly effective in late-stage trial, long-awaited results show
Health By Elizabeth Cooney ‘I’m just winging it’: Faced with confusing data on the new Alzheimer’s drug, doctors scramble to advise their patients
Biotech By Adam Feuerstein Vertex shelves second drug for inherited lung disease, raising concerns about future growth
Biotech By Felice J. Freyer — Boston Globe What’s next for the new Alzheimer’s drug? Lots of thorny issues ahead
Biotech By Matthew Herper In potential big step forward for CAR-T, Bristol Myers says its therapy outperformed stem cell transplant in blood cancer
Biotech By Damian Garde and Hyacinth Empinado Watch: SPACs are all the rage, but what are they? STAT explains
Biotech By Adam Feuerstein and Matthew Herper Biogen, FDA at odds over timing of crucial confirmatory trial of Alzheimer’s drug
Biotech By Damian Garde Biogen isn’t worried about backlash to ‘bewildering’ price of Alzheimer’s drug
Biotech By Damian Garde and Adam Feuerstein Why Biogen may be sitting on the most lucrative product in pharmaceutical history
Matt's Take By Matthew Herper By approving Biogen’s Alzheimer’s drug, the FDA is shifting its rules. That is a giant risk
Biotech By Adam Feuerstein and Damian Garde FDA grants historic approval to Alzheimer’s drug designed to slow cognitive decline
Biotech By Kate Sheridan Will you accept this capital investment? Biotech and health startups bet on a strange new reality show for crowdfunding
Biotech By Adam Feuerstein Fate Therapeutics’ natural killer cells induce responses in blood cancer patients, but for how long?
Health By Usha Lee McFarling A landmark Alzheimer’s drug approval would likely deepen racial inequities in dementia care
Biotech By Adam Feuerstein German drug maker MorphoSys to buy Constellation Pharma in $1.7 billion deal
